Endosense

Endosense is a Switzerland-based medical technology company that focuses on enhancing the effectiveness, safety, and reproducibility of catheter ablation for treating cardiac arrhythmias. Founded in 2003, the company has developed the TactiCath Quartz®, the pioneering force-sensing ablation catheter that provides real-time, objective feedback on contact force during the procedure. Clinical studies have demonstrated that utilizing contact force during ablation can reduce procedure time and minimize PV gaps at 3-month invasive follow-up. The most recent investment in Endosense was a Fr.37.40M Series C funding round on 27 November 2013. The investors in this round included GIMV, VI Partners, NeoMed Management, Sectoral Asset Management, Ysios Capital, NGN Capital, Andera Partners, and Initiative Capital Romandie. This investment reaffirms the confidence of the investor community in the potential of Endosense and its innovative technology to make significant advancements in the field of cardiac arrhythmia treatment.